GOTHENBURG, Sweden, Sept. 11, 2025 /PRNewswire/ — SKF has been awarded an `A’ score in the 2024 CDP Supplier Engagement Assessment (SEA), placing the company among the global leaders in supplier climate action and transparency. This recognition follows SKF’s earlier A rating for Climate from CDP, underscoring the Group’s commitment to environmental leadership across its operations and supply chain. 

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies, capital markets, cities, states and regions to manage their environmental impacts. The SEA evaluates how effectively companies engage their suppliers on climate-related issues, focusing on governance, targets, Scope 3 emissions, and value chain engagement. SKF achieved top scores across all categories, including an A in governance and business strategy, targets, Scope 3 emissions (including verification), and supplier engagement. 

Earlier in the year, SKF also received an A rating from CDP for climate, placing it in the top 2% of all companies scored. A record 22,700+ companies were scored in 2024, however, just 515 companies achieved an A score, underlining SKF’s sustainability commitment. 

“Being recognised by CDP for both our climate transformation progress and supplier engagement demonstrates that our strategy is not only ambitious but also credible and measurable. This recognition reflects our deep commitment to decarbonizing our own operations but also the broader value chain. Real climate impact requires collaboration, and we are proud to work closely with our suppliers to drive meaningful change,” says Sofie Runius Cederberg, Head of Sustainability at SKF. 

Within the categories of the rating, SKF scored the highest possible grade A in 15 of the 16 areas. Of particular note, SKF received an A score in the Verification (Incl. Emissions) category, where the global category average is a D score. Additionally, SKF received an A score in the Emissions Reduction Initiatives and Low Carbon Products and Value Chain Engagement categories, where the global category average is a C score. 

The full list of companies on CDP’s 2024 Supplier Engagement A List is available at: https://www.cdp.net/en/companies/companies-scores.

SKF has committed to achieving net-zero greenhouse gas emissions across its supply chain by 2050. The company continues to make strong progress toward its 2030 decarbonized operations target and accelerated its decarbonization efforts in 2024 by achieving a year-on-year emission reduction for scope 1 and 2 emissions of 32%, up from 18% in the previous year. In addition, SKF has made significant strides in renewable energy adoption. In 2024, 72% of SKF’s electricity use came from renewable sources, up from 64% in 2023. 

For more information on SKF’s path to Net-Zero emissions, click here.

Aktiebolaget SKF

      (publ)

For further information, please contact:
Press Relations: Sian How, +447970 737470; sian.how@skf.com
Investor Relations: Sophie Arnius, +46 31-337 8072; +46 705 908072; sophie.arnius@skf.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/skf-earns-top-cdp-ratings–reinforcing-climate-leadership-across-the-value-chain,c4232683

The following files are available for download:

MUNICH, Sept. 11, 2025 /PRNewswire/ — From September 9 to 12, 2025, YFORE made its debut at IAA MOBILITY 2025, showcasing the all new magnetic and supercharging technologies. YFORE’s wireless chargers fully support the latest Qi 2.2, and Qi 1.3 protocols, ensuring compatibility for various devices. Supporting mainstream power modes of MPP 25W, 15W, and EPP 15W, it meets the needs for magnetic and fast charging. Furthermore, private protocols boost power to 50W, significantly reducing charging times and saving users valuable waiting time.

On the safety front, the devices are equipped with multiple protective mechanisms, including FOD foreign object detection, OVP over-voltage protection, OCP over-current protection, and OTP over-temperature protection, effectively ensuring the safety of both devices and users. In terms of system compatibility, optional Autosar or Autosar network management functions can be integrated, easily fitting into various application scenarios.

Moreover, YFORE’s wireless charger integrates the NFC function. With a lot of experience in getting NFC Forum certifications, it can do even more things. It works with many devices like smartphones, wireless earbuds, and smart key fobs. This truly makes it a “one charger for many uses” product. It gives users a convenient, efficient, and safe wireless charging experience and leads the industry’s technological upgrade trend.

About YFORE

YFORE is a leading automotive electronics Tier 1 supplier focusing on four core areas: Intelligent Access, Intelligent Cockpit, Smart Mirror, Intelligent Mechatronics. Established in 2002, YFORE has expanded global presence withR&D centers and manufacturing facilities across China, theUSA,Germany, and the Netherlands. It has collaborated with over 30 OEMs, maintaining the No. 1 market share in Category I CMS for eight consecutive years and the No.1 market share in China’s EV startup segment(data source: shujubang.com).

In the future, YFORE will continue to focus on technological innovation, improving products and solutions to meet international standards, providing high-quality localized services for global partners, and contributing to industry development, enriching enjoyable mobility for users worldwide.

FUYANG, China, Sept. 11, 2025 /PRNewswire/ — YR Fitness, one of China’s largest commercial gym equipment manufacturers, will showcase its latest innovations at the Dubai Muscle Show 2025, the Middle East’s leading fitness exhibition. The company will debut the C4 Revival Series, a new strength training line featuring advanced adjustability and modern design, as part of its push to expand partnerships across global markets.

With customers in more than 100 countries, YR Fitness views the Dubai exhibition as a key opportunity to connect with international distributors, highlight its commitment to independent design, and strengthen its position as a trusted supplier in the global fitness industry.

Showcasing Strength at Dubai Muscle Show 2025

YR Fitness is proud to announce that we will be exhibiting at the Dubai Muscle Show 2025, the premier fitness industry event in the Middle East. This show is a global stage where gym owners, trainers, and distributors gather to experience the latest innovations in fitness equipment. For us, it’s an opportunity to showcase our newest strength training solutions, connect with international partners, and continue building our reputation worldwide.

Looking ahead, YR Fitness is already preparing for an exciting schedule of global exhibitions in 2026, including HFA USA, FIBO, and the China Sport Show. Each event is a chance for us to demonstrate why YR Fitness is recognized as one of China’s top commercial gym equipment manufacturers, trusted by fitness professionals in over 100 countries for consistent quality.

Who We Are

Founded in 1997 with roots dating back to 1991, YR Fitness has nearly three decades of experience in designing and producing professional-grade gym equipment. From repairing national team machines in our early years to becoming a global supplier for the U.S. Army, the Chinese Olympic Team, and major fitness chains such as Lefit (China) and Power World Fitness Centres (Sri Lanka), our story is one of steady growth and innovation.

Headquartered in Anhui with factories in Fuyang, an R&D center in Beijing, and a sales hub in Shanghai, we combine manufacturing scale with design leadership. Today, YR Fitness is one of China’s largest and leading commercial gym equipment manufacturers, supplying products trusted by gyms, training centers, and institutions worldwide.

Innovation in Strength Equipment

At YR, we specialize in strength equipment and independent design. Unlike many manufacturers who simply copy existing models, we create equipment from scratch. Our philosophy is simple but powerful: “Design is how it works. Simple but Significant.”

Over the years, we have secured 200+ patents and developed multiple landmark series that changed the industry:

• 73 Tough Series (2008): The world’s first pin-loaded machines with converging and diverging movement paths, setting a new benchmark for natural biomechanics.
• 61A Racing Series (2016): Compact, efficient, and incredibly durable—some units have been in commercial operation for more than 20 years.
• C4 Revival Series (2025): Our latest innovation, combining modern aesthetics with unmatched adjustability, advanced features like rotating grips and isolation attachments, and an ever-expanding lineup.

This commitment is why YR Fitness is recognized as one of the best strength equipment suppliers in China, especially in plate-loaded and pin-loaded gym machines.

100% Original Design & Founder’s Vision

At the heart of YR Fitness is a commitment to 100% original design. Since our founding, we have never relied on imitation; instead, we build every piece of equipment from the ground up. Our philosophy—”Design is how it works. Simple, but Significant”—guides every product we create. From the world’s first pin-loaded machines with converging and diverging paths in the 73 Series, to the modern adjustability and aesthetics of the C4 Revival Series, YR has continually pushed the boundaries of functionality, ergonomics, and durability. This dedication has earned us more than 200 patents and recognition as one of the few Chinese fitness equipment manufacturers capable of competing with leading international brands.

Behind this philosophy is our founder and chief designer, George Yang. With roots dating back to 1991, when he first repaired equipment for national sports teams, George has always believed that fitness equipment should empower athletes through both performance and design. His leadership combines technical precision with artistic vision, supported by a design team trained at world-class institutions such as the Royal College of Art and Central Saint Martins. Together, they bring a unique blend of engineering, biomechanics, and creativity that defines every YR product. George’s lifelong mission—to create equipment that not only lasts but inspires—continues to shape YR Fitness as a pioneer in the global fitness industry.

For George, innovation is never optional—it is the foundation of lasting success. That’s why he pushes YR to keep reinventing, ensuring our products remain at the cutting edge of design and performance. As George often says: “We make products with heart. We make products with standard.”

OEM, ODM, and Customization

One of the key advantages of YR Fitness is our ability to help brands stand out through OEM and ODM solutions.

One of YR Fitness’s greatest strengths lies in our ability to bring brands to life through OEM services. When clients come to us with their own design concepts, logos, or specifications, our factory turns these visions into reality. Every detail—from the choice of steel tubing and upholstery to the final assembly and finish—is executed according to the client’s requirements while maintaining our strict commercial standards. This means gyms and distributors can launch their own equipment lines without building a factory from scratch, while still ensuring the machines meet international certifications and performance benchmarks. By offering OEM at scale, YR helps partners reduce costs, accelerate market entry, and maintain complete control over their branding.

For ODM (Original Design Manufacturing), YR offers a fast-start private-label route built on our existing equipment models—so you get high-quality machines that reflect your brand without starting from scratch. Choose the models you want and customize them end-to-end: add your logo (send a PSD or AI file and our consultant will recommend the right logo technology for each material/surface), customize your color using our color board (note: some color options are fixed—contact us for details), request functional personalization (e.g., adjust specific parts, create multi-grip handles, or add adjustability to fixed parts), and pick your packaging (we can meet the requirements for most common packaging styles or advise if you need suggestions). This ODM path delivers a branded, cohesive lineup—quick, practical, and consistent across your whole range.

Beyond OEM/ODM, YR offers extensive customization options:

• Colors: Choose from a wide color board for both frames and upholstery to match your branding.
• Logos: Add your logo anywhere on the equipment; just send us a PSD or AI file and our team will handle the rest.
• Materials & Accessories: Select different materials, grips, and attachments to personalize your machines.

This level of flexibility ensures that whether you’re outfitting a boutique studio or a large-scale fitness chain, YR can tailor the equipment to your identity.

Quality That Defines Standards

YR Fitness is recognized as one of top fitness equipment supplier in China, delivering quality that competes directly with international premium brands. In an industry where some manufacturers cut corners, YR Fitness sets the bar for quality.

While many brands use 1.8–2.5 mm tubing, we insist on Q235 steel with a 3.0 mm wall thickness, which is 2–3 times stronger and compliant with ASTM F1250 standards. This thickness refers to the raw material itself—not the coated measurement that some suppliers use to mislead buyers.

Every detail of our machines is built for durability, safety, and aesthetics:

• Lifetime warranty on main frames, far exceeding the typical 10-year industry standard.
• German robotic laser cutting and welding for flawless construction.
• Hidden screw nuts for a smooth, safe, and modern finish.
• Industrial-grade sealed bearings, tested for over 30 years of performance with zero complaints.
• Steel cables tested at 300 kg for 24 hours nonstop—over 28,800 pulls without breaking.
• Electrostatic powder coating and stainless/aluminum parts proven to resist sweat corrosion.
• High-density foam (57–67 kg/m³) and premium PVC upholstery: sweat-proof, crack-resistant, and built to last.

This attention to detail is why gym owners from Malaysia to the U.S. praise our equipment as “very high quality, solid and durable, reasonably priced, and extremely satisfying.”

Certified and Globally Compliant

YR Fitness is committed to meeting the highest international quality and safety benchmarks. Our equipment carries multiple globally recognized certifications, including CE, TÜV, and ISO (specifically ISO 20957 standards), ensuring each product—from multi-stations to treadmills—complies with rigorous safety and performance requirements.

We also maintain internationally recognized intellectual property protections, including patents and trademarks registered with bodies such as EUIPO, UK Trademark Office, USPTO (USA), and India IP Office—evidence of our leadership in original product design.

This portfolio of certifications and IP safeguards not only testifies to the safety and quality of YR equipment but also reinforces YR Fitness’s position as a leading Chinese manufacturer of commercial gym equipment, competing with global fitness brands.. When you partner with YR, you gain access to gym equipment you can trust—not only today, but for years to come.

Full Product Portfolio

YR offers a complete range of commercial fitness solutions. Our strength equipment is built to combine smooth biomechanics, long-lasting durability, and flexible customization—qualities that make it a strong alternative to international brands.

• Strength Machines: Chest press, lat pulldown, 7333 Smith Machine and 7333A 3D Smith Machine, G2050 and G2049 Power Racks, and Pull Over machines like the G2039.
• Multi-Stations: 4-station F2001, 6-station 6280A, 9-station F2003, 10-station gyms, and even 14-station F2004 for high-traffic training environments.
• Free Weights: Barbells, dumbbells, kettlebells, and weight plates, all designed for commercial use with ergonomic grips and durable finishes.
• Cardio: Treadmills, ellipticals, and bikes engineered for heavy-duty gym usage.
• Accessories: Battle ropes, resistance bands, yoga mats, and storage systems.

Whether you need a few machines or a complete gym package, YR provides the variety and flexibility to meet your needs. More importantly, YR Fitness is recognized as a one-stop commercial fitness equipment solutions provider. From strength machines to cardio equipment, from free weights to accessories, and even the extra details your gym may require, we deliver everything through our manufacturing capacity and a trusted network of partners. This ensures that every customer receives a complete, seamless solution tailored to their business model and training needs.

Competitive Pricing and Partnership

High quality doesn’t have to come at a high cost. As a leading commercial gym equipment manufacturer, YR Fitness delivers big-brand quality at about one-fifth the price of top international brands through our factory-direct model. By removing middlemen, we ensure transparent pricing and faster communication, allowing our customers to access premium equipment without unnecessary markups. To support businesses of every size, we accept trial orders without any minimum quantity, while larger orders can be efficiently managed with a minimum of one 20-foot container.

Beyond pricing, we are committed to building long-term relationships, offering flexible partnership models that include OEM, ODM, distribution, and agency cooperation. With exclusive territory agreements, bulk discounts, and dedicated support from our sales team, our partners gain not only better margins but also a trusted manufacturer standing behind them every step of the way. Choosing YR means choosing reliability, affordability, and a true partnership for growth.

Become a Distributor: Exclusive Benefits with YR

At YR Fitness, we don’t just manufacture equipment—we build partnerships. Becoming an authorized YR distributor opens the door to a range of exclusive benefits designed to help you succeed in your market. As our distributor, you enjoy special discounts on all orders, giving you a competitive edge while maximizing your margins.

We provide professional marketing support, including catalogs, images, videos, and social media assets, to help you promote effectively. In addition, we offer professional customer service and technical support—so your team can confidently and quickly solve technical problems in the after-sales process.

As our partner, you’ll have guaranteed spare parts support, with free parts provided during the warranty period, ensuring your clients never face downtime. We also enforce territorial protection, meaning YR will not assign another distributor or sell directly in your designated area, giving you full control over local inquiries and customers.

Most importantly, we see distributors as long-term partners. With YR, you gain not just premium equipment at factory-direct pricing but also a trusted ally committed to your growth and success in the fitness industry.

After-Sales and Warranty

YR’s commitment extends far beyond delivery. We are one of the few fitness equipment manufacturers in China to offer a lifetime warranty on main frames, setting a benchmark that surpasses the typical industry standard. For other components, we offer graded coverage—up to eight years on treadmill frames, five years on bars and plates, and specific terms for parts depending on their function and usage. Our 24-hour customer support ensures that clients around the world receive immediate assistance whenever they need it, while our continuous supply of spare parts guarantees that gyms can operate without downtime.

This comprehensive protection, paired with responsive service, makes YR the partner of choice for fitness facilities that demand long-term reliability under high-frequency, heavy-duty conditions.

Green Factory and Sustainability

YR Fitness is proud to be a Green Factory, aligning with global sustainability standards.

Our eco-friendly practices include:

• Energy-saving design with optimized layout, insulation, and natural lighting.
• Efficient production to reduce waste and conserve resources.
• Use of sustainable materials, including recycled and ethically sourced options.
• Lifecycle assessments to ensure products remain environmentally responsible from production to usage.

Layout Solutions and Quick Quote Tool

Opening a gym is more than buying equipment—it’s about designing a space that works. YR provides all commercial gyms with professional layout advice and detailed design drawings, where you simply send us your floor plan (CAD, PDF, or even hand-drawn) and our team delivers a full design within two business days. We optimize for safety, flow, and branding consistency, whether your gym is 80 m² or 1,200 m².

To make procurement even easier, our Quick Quote tool allows you to choose products not only by equipment series but also by the muscle groups you want to target. This gives gym owners complete flexibility: you can decide in advance how many machines you need for legs, shoulders, chest, or back, and then freely mix and match models across different series to build the perfect lineup. Once your selection is complete, simply submit your list and our consultants will provide tailored pricing, customization options, and logistics guidance to help you move forward with confidence.

Guidance for Gym Owners

YR doesn’t just sell equipment—we guide gym owners through the entire journey. Our blogs and resources cover everything from how to import gym equipment from China, to buying guides for strength machines, to step-by-step plans for opening gyms in cities, small towns, or even women-only facilities.

We provide checklists, templates, and practical advice on market research, financing, legal setup, layout planning, member retention, and more. For new entrepreneurs, YR is not only a supplier but a strategic partner.

Conclusion

From Dubai Muscle Show 2025 to fitness clubs across the globe, YR Fitness continues to shape the future of commercial gym equipment. YR Fitness is recognized as a leading Chinese fitness equipment manufacturer, with nearly 30 years of expertise, 200+ patents, and customers in more than 100 countries.

At our core, we specialize in strength equipment and independent design—a philosophy that drives us to innovate continuously. For gym owners, distributors, and fitness entrepreneurs worldwide, YR Fitness is not only a manufacturer of commercial fitness equipment but also a strategic partner, providing complete solutions including OEM/ODM, sustainability, and world-class after-sales support.

With YR, you’re not just buying equipment—you’re investing in a partner dedicated to your success.

YR Fitness

Website: yanrefitness.com
Email: sales@yanrefitness.com
Phone: +86 186 2119 7751

• Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb)
• New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented for the first time at IHC^1,2
• Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term reduction in monthly migraine days (MMDs) and improvements in patient-reported outcomes^1,2

VALBY, Denmark, Sept. 11, 2025 /PRNewswire/ — H. Lundbeck A/S (Lundbeck) is advancing leadership in migraine with a comprehensive collection of datasets to be presented at the 2025 International Headache Congress, taking place in São Paulo (Sept 10-13).^1-6 Among data presented, Lundbeck will announce the full results of the 12-week, open-label extension of the RESOLUTION trial investigating eptinezumab for the prevention of migraine in patients with chronic migraine and associated medication overuse headache (MOH) who also received standardized patient education.¹ In addition, new data from the SUNSET open-label extension trial in Japanese patients with chronic migraine will be shared with the scientific community for the first time.²

“Migraine is a chronic, disabling disease that disrupts lives and demands a comprehensive, long-term management approach,” said Johan Luthman, EVP, and Head of Research & Development at Lundbeck. “Patients deserve preventive treatments that not only deliver early relief but sustain their impact over time. The RESOLUTION and SUNSET trials show that patients who experience an early, clinically significant response with eptinezumab continue to maintain this response long-term. This offers renewed hope for those severely impacted by the burden of migraine.”

In the phase 4 RESOLUTION trial,⁷ the early, clinically meaningful improvements in migraine symptom and burden observed during the initial placebo-controlled period were sustained during the open-label extension period. Around 50% of patients achieved a ≥50% reduction from baseline in monthly migraine days (MMDs) and achieved approximately nine days fewer MMDs at the end of the 12 week OLE, compared to baseline at the start of the RESOLUTION trial (baseline was 20.9 MMDs).¹

Additionally, the primary results of the SUNSET trial will be presented at IHC. SUNSET was a 60-week open-label extension of the Asian registrational SUNRISE trial, designed to evaluate the long-term safety, tolerability and efficacy of eptinezumab in a Japanese population with chronic migraine.²

In the trial the symptom reduction observed within the first 12 weeks of treatment with eptinezumab (SUNRISE trial) was maintained across the open-label period.² The proportion of participants with a ≥50% or ≥75% MMD reduction from baseline was sustained throughout the trial, with 35.7% of patients achieving a 50% reduction in MMD by week 49-60. A trend towards increasing ≥75% response rate was also observed across the 60-weeks extension period.²

Eptinezumab was well tolerated across both trials,^1,2 similar to previous trials in migraine prevention and to the current labelled safety information in the United States prescribing information and the EU Summary of Product Characteristics.

These data collectively underscore the long-term effectiveness, tolerability, and safety of eptinezumab in addressing the needs of patients severely impacted by migraine, and underscores Lundbeck’s commitment to lifting the burden of migraine for patients globally.

Details of Lundbeck’s scientific program at IHC:

Satellite symposium

Revolutionizing patient care through science: From neuropeptides to higher standards in migraine prevention. Speakers: Peter J. Goadsby, Gisela Terwindt and Stewart Tepper, Saturday 13 September: 13:00-14:30

Oral presentations

Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache: 24-week results of the RESOLUTION trial. Presented by Henrik W Schytz. Saturday 13 September: 16:00-17:00¹

Eptinezumab improved patient-reported disease burden and quality of life in a predominantly Asian population with chronic migraine: Secondary results from the SUNRISE trial. Presented by Patricia Pozo-Rosich. Saturday 13 September: 10:30-11:30³

Patient perspectives of migraine symptomology: Insights from exit interviews from the anti-PACAP antibody Phase 2 HOPE trial for migraine prevention. Presented by Richard Lipton. Saturday 13 September: 10:30–11:30.⁴

ePoster presentations

Eptinezumab reduced disease burden in chronic migraine and medication-overuse headache in patients also receiving patient education: Results from the placebo-controlled RESOLUTION trial. Tepper SJ, et al. Saturday 13^th September⁵

Efficacy and safety of eptinezumab in chronic migraine: Randomized controlled trial in a predominantly Asian population. Yu S, et al. Friday 12^th September⁶

Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: The 60-week, open-label SUNSET trial. Takeshima T, et al. Saturday 13^th September²

About migraine and medication-overuse headache (MOH)

Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound.⁸

Migraine is the second leading cause of years lived with disability (YLD) among all diseases, and it is the top YLD cause among patients aged 15 to 49 years, according to the Global Burden of Disease study.⁹ As the most prevalent neurological disorder in people aged <50 years, migraine imposes both a social and financial burden. In Europe, migraine alone affects close to 50 million people costing the economy EUR 18 billion annually according to the Cost of Brain Disorders in Europe¹⁰ study and this is without the indirect cost associated with presenteeism (i.e. productivity losses due to reduced efficiency of persons who are not sufficiently ill to be absent from work).

Repeated migraine attacks, and often the constant fear of the next one, damage family life, social life, and work life. Furthermore, increased use of acute headache medications may lead to central sensitization and decreased effectiveness of the acute headache medication, resulting in a cycle of increased number of headache days requiring even further increased amounts of acute headache medication. Without proper migraine management, this process results in worsening migraine and may lead to the development of chronic migraine and MOH.¹¹ The secondary headache of MOH is a common complication among individuals with primary headache disorders like chronic migraine.

About the RESOLUTION trial

RESOLUTION was a phase 4, randomized, placebo-controlled trial designed to evaluate the efficacy of eptinezumab versus placebo in patients with chronic migraine and associated medication-overuse headache (MOH) who also received standardized patient education.⁷ RESOLUTION included a 12-week double-blind, placebo-controlled period followed by a 12-week open-label extension. The participants in the RESOLUTION trial were mainly from European countries.

RESOLUTION is the first randomized controlled trial to assess the efficacy of an anti-CGRP treatment in combination with structured patient education in chronic migraine and MOH. The trial enrolled 608 participants with dual diagnoses of chronic migraine and MOH, and participants were randomly allocated to one of two treatment groups, brief educational intervention (BEI) and eptinezumab (100 mg; n = 305) or BEI and placebo (n = 303), in a 1:1 ratio. BEI involves a short screening followed by individual feedback on how and why acute migraine medication use should be reduced, and this approach to patient education has been shown to result in long-term medication reductions for patients with MOH.

At the end of Week 12, 584 participants continued in the 12-week, open-label extension, where all participants received eptinezumab 100 mg. Clinical efficacy endpoints included change from baseline in MMDs, ≥50% and ≥75% responder rate and change from baseline in monthly days with acute medication use. Key secondary endpoints included reductions in headache-related burden, migraine-related disability, work productivity loss, activity impairment, and the safety and tolerability of eptinezumab in this patient population.

About the SUNSET trial

The SUNSET trial (NCT05064371) was an extension of the phase 3, multiregional, randomized, double-blind, placebo-controlled SUNRISE trial (NCT04921384) conducted in adults (18–75 years) diagnosed with chronic migraine.² 159 Japanese participants who completed SUNRISE were enrolled and treated in SUNSET after completing 12-week, randomized, double-blind treatment with IV eptinezumab 100 mg, 300 mg, or placebo. SUNSET comprised a 60-week open-label treatment period (during which participants received IV eptinezumab every 12 weeks [5 doses total] and completed a daily electronic diary) and an 8-week safety follow-up period. All participants received eptinezumab 100 mg at baseline in SUNSET, participants who did not achieve ≥50% reduction from SUNRISE baseline in monthly migraine days (MMDs; SUNSET Weeks 1–12) had their dose increased to 300 mg at SUNSET Week 12 and onward.

The primary endpoints investigated long-term safety and tolerability, including treatment emergent adverse events (TEAEs). Secondary endpoints included change from baseline in the number of MMDs, ≥50% and ≥75% migraine responder rates (MRRs), and Patient Global Impression of Change (PGIC) score. Exploratory endpoints included change from baseline in the Migraine-specific Work Productivity and Activity Impairment (WPAI:M) questionnaire domain scores.

About Vyepti® (eptinezumab)

Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III clinical trials (PROMISE-1 in episodic migraine¹² and PROMISE-2 in chronic migraine¹³), where eptinezumab met its primary endpoint of decrease in MMDs over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of eptinezumab as early as Day 1 post-infusion. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions.

VYEPTI (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide.

Contacts
Marie Petterson
Jens Høyer
Head of Media Relations, Corp. Communication
Vice President, Head of Investor Relations
MEEP@lundbeck.com
JSHR@lundbeck.com 
+45 29 82 21 82
+45 30 83 45 01

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References: 

1.  Jensen RH et al. Oral presentation at IHC 2025

2.  Takeshima T et al. ePresentation at IHC 2025

3.  Yu S et al. Oral presentation at IHC 2025

4.  Lipton RB et al. Oral presentation at IHC 2025

5.  Tepper SJ et al. ePresentation at IHC 2025

6.  Yu S et al. ePresentation at IHC 2025

7.  Jensen RH, et al. Front. Neurol. 2023; 14:1114654

8.  Villalón CM. Pharmacol Ther. 2009;124(3):309-323

9.  Steiner TJ, et al. J Headache Pain. 2018;19(1):17

10.  Gustavsson A, et al. Eur Neuropsychopharmacol. 2011;21(10):718-79

11.  Lipton RB, et al. J Neurol. 2023; 270, 5692–5710

12.  Ashina M, et al. Cephalalgia. 2020;40(3):241-254

13.  Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377

CONTACT: 
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-showcases-new-clinical-migraine-data–including-long-term-preventive-effectiveness-of-vyept,c4232539

The following files are available for download: